Buy/High Risk Rating Given To Lexicon Pharmaceuticals By Citi Analysts
Lexicon Pharmaceuticals, Inc’s (NASDAQ: LXRX) lead drug [telotristat etiprate] has orphan status, while the diabetes drug [sotagliflozin] addresses an underserved market. Citi’s Yigal Nochomovitz initiated coverage of the company with a Buy/High rating and a price target of $21.
Telotristat etiprate met primary endpoints in two Phase 3 trials and was granted Priority Review by the FDA, with a PDUFA date of November 30, 2016. A timely approval and launch of the drug would support Lexicon Pharma’s stock in the near term, analyst Yigal Nochomovitz mentioned. He estimated peak sales of telotristat at ~$380M for the US and at ~$650M for worldwide sales.
Sotagliflozin has significant potential in diabetes, particularly type 1 [T1DM] and renally impaired type 2 [T2DM]. Positive Phase 2 data suggests the drug would succeed in the ongoing pivotal Phase 3 trials, Nochomovitz said.
“Lexicon's first-to-market advantage in T1DM is important given the limited/underserved market vs T2DM. Our work suggests that sotagliflozin's potentially differentiated benefit in patients with renal (kidney) impairment could be key to penetrating the broader T2DM setting,” the analyst wrote. He estimated peak worldwide sales of sotagliflozin at ~$2.1B for T1DM and at ~$2.0B for T2DM.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email email@example.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for LXRX
|Oct 2016||H.C. Wainwright||Initiates Coverage on||Buy|
|Aug 2016||Stifel Nicolaus||Maintains||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.